|
Published by: Business Insights
Published: Feb. 1, 1999 - 124 Pages
Table of Contents
Executive summary
- Introduction
- Genomic research: understanding the technology
- Current applications
- Key players in genomic research
- Future issues
Chapter 1 Introduction
- Summary
- Current status of R&D productivity
- The importance of R&D to the pharmaceutical industry
- R&D expenditure
- R&D timescale
Chapter 2 Genomic research: understanding
the technology
- Summary
- Introduction
- Target identification
- Genome mapping
- Positional cloning
- Random sequencing
- Genetics of model organisms
- Two-hybrid assay
- Hybridisation on a chip
- Differential display
- Massively Parallel Signature Sequencing (MPSS)
- 2-D gel electrophoresis
- Target validation/Assay Development
- Gene knockouts
- Cellular assays
Chapter 3 Current applications
- Summary
- Introduction
- Target identification
- Positional cloning
- Random sequencing
- Proteomics
- Applying bioinformatics
- Initial functional analysis
- Target validation
- Animal models
- Cellular assays
- Antisense RNA and ribozymes
- Assay development
- Cellular assays
- Genetically-modified model organisms
- Genomics and the preclinical stage
- Genetic variation and clinical development
- Pharamcogenomics
- Applying pharmacogenomics
- Pharmacogenmics and clinical testing
- Genetic testing for disease
Chapter 4 Key players in genomic research
- Summary
- Introduction
- Drivers to expanding technology platforms
- Incyte Pharmaceuticals
- The use of DNA microarrays
- Adding further value to the databases
- Developing diagnostic tests
- Axys Pharmaceuticals
- Aurora Biosciences
- Future growth using its proprietary UHTSS
- Affymetrix
- Millennium Pharmaceuticals
- Millennium's subsidiaries and their corporate alliances
- Myriad Genetics
- Myriad's products
- Myriad's collaborations
- Consolidation within the biotechnology sector
- Role of pharmaceutical companies
- Drivers of outsourcing
- Contracting vs alliances
- Alliances vs acquisitions
- Differences in EU and US strategies
- Outsourcing genomic research
- Managing a diverse portfolio of research projects
- Investment patterns by leading pharmaceuticals
Chapter 5 Future issues regarding
Genomics
- Summary
- Impact on drug research
- Target identification
- Target validation
- Effect on preclinical development
- Impact on drug development
- Effect on clinical development
- Impact on disease management
- Genetic testing of disease
- The effect of pharmcogenomics
- New market opportunities
- Rise of diagnostic testing
- Designer drugs
Chapter 6 Appendix
- Glossary
- References
- Index
List of Figures
- Figure 1.1: Ethical pharmaceutical R&D expenditure for US-based companies, 1980-1998
- Figure 1.2: Resource allocation in the research and development process, 1996
- Figure 1.3: Technologies and applications in the early stages of drug discovery
- Figure 1.4: Opportunities for generating revenues from genomics
- Figure 2.5: Generating a genome map
- Figure 2.6: Positional cloning
- Figure 2.7: Mechanics of the two-hybrid assay
- Figure 2.8: Gene chips
- Figure 2.9: Methodology behind differential display
- Figure 3.10: Competitive assessment of key technologies
- Figure 4.12: Stages of drug discovery covered by selected companies' technologies
- Figure 4.13: Drivers to expanding technology platforms
- Figure 4.14: Incyte's products, technologies and corporate activities
- Figure 4.15: Axys's products and technologies
- Figure 4.16: Aurora's products and technologies
- Figure 4.17: Affymetrix's products and technologies
- Figure 4.18: Development of Affymetrix's services and products
- Figure 4.19: Millennium's products and technologies
- Figure 4.20: Myriad's products and technologies
- Figure 5.21: The impact of drug discovery technologies on reducing development time
List of Tables
- Table 1.1: Drug development timescale in US, 1960-1996
- Table 1.2: Efficiency of the drug development process, 1998
- Table 1.3: Competitive assessment of key technologies
- Table 3.4: Corporate collaborations in genomics, 1998
- Table 4.5: Selected research consortiums, 1998
- Table 4.6: Selected alliances established by leading pharmaceutical companies
- Table 5.7: Types and uses of genetic diagnostic tests
AbstractAlthough its possibilities have not yet been fully realised, experts view genomics as pivotal to improving innovation in the drug discovery process. How will genomics impact on drug R&D? What are the key genomic technologies being used? Which companies are the most active in genomic research? How could pharmacogenomics reshape the healthcare market in the future? Based upon our exclusive primary research with over 50 key opinion leaders, this report provides the vital strategic insight you need to: Identify the basic principles behind the main genomic technologies and how they can improve drug R&D and disease management Understand how the business strategies of key genomics companies are evolving to meet the needs of both their internal research departments and also their external clients Evaluate the impact of genomics and pharmacogenomics into the 21st century.
Get Full Details About This Report >>
|
